Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Summary

Determine the safety of a combination of IFN, celecoxib, and rintatolimod for patients with recurrent colorectal cancer. This will also test whether the above combination can help the immune system to fight the tumors. The results will allow the investigators to determine the "preferred" combination for subsequent extended studies.

Timeline

Start

2012-10

Primary completion

2016-04-08

Completion

2017-04-08

Drugs

Indications